XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 5,774,356 $ 9,968,600
Short-term investments available-for-sale, at fair value 34,955,936  
Accounts receivable 3,481,994 6,356,268
Inventory, net of allowance of $62,329 at June 30, 2018 and $62,142 at December 31, 2017 1,002,549 1,180,521
Prepaid expenses and other 845,170 443,068
Total current assets 46,060,005 17,948,457
Deferred offering costs   2,953
Deferred MidCap revolving loan costs 75,184  
Property and equipment, net 2,888,995 3,304,890
Total assets 49,024,184 21,256,300
Current liabilities:    
Accounts payable 1,306,917 2,438,798
Accrued liabilities 2,427,776 3,746,786
Contract liabilities - current 315,592 665,882
NuvoGen obligation - current 605,979 496,442
Growth Term Loan payable - net of discount and debt issuance costs   5,793,599
Other current liabilities 199,164 200,460
Total current liabilities 4,855,428 13,341,967
NuvoGen obligation - non-current, net of discount 6,970,277 7,520,913
Convertible note, related party - net of debt issuance costs 2,967,487 2,960,760
MidCap Term Loan payable - net of discount and debt issuance costs 6,626,886  
Other non-current liabilities 389,490 492,197
Total liabilities 21,809,568 24,315,837
Commitments and Contingencies (Note 14)
Stockholders’ equity (deficit):    
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2018 and December 31, 2017, 28,414,524 shares issued and outstanding at June 30, 2018 and 13,929,763 shares issued and outstanding at December 31, 2017 28,414 13,929
Additional paid-in-capital 171,246,278 131,492,595
Accumulated other comprehensive loss (11,339)  
Accumulated deficit (144,048,737) (134,566,061)
Total stockholders’ equity (deficit) 27,214,616 (3,059,537)
Total liabilities and stockholders' equity (deficit) $ 49,024,184 $ 21,256,300